Hopital Fondation Adolphe De Rothschild — Sponsor Intelligence | 7 EU Trials

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

5 Recruiting

1 Completed trials

1 Countries active

21 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 3 Phase II: 3 Phase I (Other): 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Aneurysm ruptured 1 Ischaemic stroke 1

Top IMPs

PARACETAMOL 2 ALLOGENEIC BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS 1 AZATHIOPRINE 1 BEVACIZUMAB 1 DEXAMETHASONE, OXYTETRACYCLINE 1 DEXCHLORPHENIRAMINE MALEATE 1 DORNASE ALFA 1 FLUORESCEIN SODIUM 1 GADOBUTROL 1 GLENZOCIMAB 1 HUMAN SERUM ALBUMIN 1 IBUPROFEN 1

All trials

7 total

SYMBOL CLINICAL : Treatment of severe ocular chemical burns by subconjunctival injection of allogeneic mesenchymal stem cells: a multicentre… Pending

2023-509713-37-00 Phase II 1 country ALLOGENEIC BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS; DEXAMETHASONE, OXYTETR…
Efficacy of daily IV administration of dornase alfa for up to 14 days post subarachnoid haemorrhage on functional independence at 6 months: … Recruiting

2023-509627-40-01 Phase III 1 country DORNASE ALFA
Evaluation of the safety of a strategy combining etanercept administration with repeated contrast ultrasound in patients with Alzheimer's d… Recruiting

2023-505714-19-00 Phase I (Other) 1 country
Immediate corticosteroid therapy and rituximab to prevent generalization in ocular myasthenia gravis: a PROBE-type multicenter, open-label, … Recruiting

2023-506656-24-00 Phase III 1 country AZATHIOPRINE; DEXCHLORPHENIRAMINE MALEATE; METHYLPREDNISOLONE HEMISUCCINATE; PAR…
BevacizuMAV : Evaluation of the efficacy and safety of anti-angiogenic treatment with intravenous bevacizumab in patients with symptomatic c… Recruiting

2023-508464-30-00 Phase II 1 country BEVACIZUMAB
For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment… Recruiting

2023-505420-62-00 Phase III 1 country OCRELIZUMAB
Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy Ended

2023-509615-92-00 Phase II 1 country GADOBUTROL; GLENZOCIMAB

Showing 1–7 of 7 trials

← All sponsors A–Z